Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash Flows From Operating Activities:
Net Income (Loss)	$ (66,434,000)	$ 71,327,000
Adjustments to reconcile net income (loss) to net cash and cash collateral posted to counterparties provided by (used in) operating activities:
Net amortization of premium on Agency Securities	7,486,000	15,795,000
Realized gain on sale of Agency Securities, available for sale	0	(7,354,000)
Loss on Agency Securities, trading	254,389,000	62,586,000
Loss on short sale of U.S. Treasury Securities	0	28,000
Stock based compensation	935,000	1,199,000
Changes in operating assets and liabilities:
(Increase) decrease in accrued interest receivable	(6,064,000)	1,952,000
Increase in prepaid and other assets	(917,000)	(7,715,000)
Change in derivatives, at fair value	(354,525,000)	(117,813,000)
Increase (decrease) in accrued interest payable- repurchase agreements	20,000	(610,000)
Increase in accounts payable and other accrued expenses	3,820,000	1,802,000
Net cash and cash collateral posted to counterparties provided by (used in) operating activities	(83,704,000)	21,197,000
Cash Flows From Investing Activities:
Purchases of Agency Securities	(1,778,122,000)	0
Principal repayments of Agency Securities	131,356,000	278,722,000
Proceeds from sales of Agency Securities	0	405,050,000
Disbursements on reverse repurchase agreements	0	(391,125,000)
Receipts from reverse repurchase agreements	0	391,125,000
Increase in cash collateral posted by counterparties	378,598,000	120,426,000
Net cash and cash collateral posted to counterparties provided by (used in) investing activities	(2,452,654,000)	804,170,000
Cash Flows From Financing Activities:
Issuance of common stock, net of expenses	46,427,000	52,960,000
Proceeds from repurchase agreements	16,191,551,000	7,044,307,000
Principal repayments on repurchase agreements	(13,699,584,000)	(7,769,582,000)
Series C Preferred stock dividends paid	(2,995,000)	(2,486,000)
Common stock dividends paid	(29,108,000)	(20,057,000)
Net cash and cash collateral posted to counterparties provided by (used in) financing activities	2,506,291,000	(666,685,000)
Net increase (decrease) in cash and cash collateral posted to counterparties	(30,067,000)	158,682,000
Cash and cash collateral posted to counterparties - beginning of period	356,216,000	171,668,000	$ 171,668,000
Cash and cash collateral posted to counterparties - end of period	326,149,000	330,350,000	$ 356,216,000
Supplemental Disclosure:
Cash paid during the period for interest	19,371,000	4,193,000
Non-Cash Investing Activities:
Receivable for unsettled sales	47,713,000	358,670,000
Payable for unsettled purchases	(687,250,000)	(295,991,000)
Net unrealized loss on available for sale Agency Securities	(78,538,000)	(34,880,000)
Amounts receivable for issuance of common stock	8,009,000	0
Series C Preferred Stock
Cash Flows From Financing Activities:
Issuance of Series C Preferred stock, net of expenses	0	28,173,000
Series C Preferred stock dividends paid	(2,995,500)
U.S. Treasuries
Adjustments to reconcile net income (loss) to net cash and cash collateral posted to counterparties provided by (used in) operating activities:
Net amortization (accretion) of U.S. Treasury Securities	(801,000)	0
Loss on U.S. Treasury Securities	78,387,000	0
Cash Flows From Investing Activities:
Purchases of U.S. Treasury Securities	(2,654,611,000)	(390,126,000)
Proceeds from sales of U.S. Treasury Securities	$ 1,470,125,000	$ 390,098,000